Skip to main content
. 2018 Jun 15;9(46):28030–28041. doi: 10.18632/oncotarget.25555

Figure 3. Roniciclib decreases the level of Aurora A and accumulates cells in G2 phase in MTC cells.

Figure 3

(A) Cell cycle distribution was analyzed by evaluating the DNA content using flow cytometry in TT and DRO81-1 cells treated with placebo or roniciclib (100 nmol/L) for 24 h. Statistical analyses revealed that roniciclib (100 nmol/L) decreased cell population in S phase and accumulated cells in G2/M phase at 24 h in TT and DRO81-1 cells. (B) The proportion of MTC cells in mitosis was assessed after treatment with roniciclib (100 nmol/L) or placebo for 24 h. Cells were stained with DAPI and chromosome characteristics were evaluated using immunofluorescence confocal microscopy. Mitotic index was assessed with a minimum of 1313 cells and counted from at least ten different fields for each condition. Roniciclib significantly decreased the proportion of cells in mitosis in TT and DRO81-1 cell lines. (C) Cells were treated with roniciclib (100 nmol/L) or placebo for 24 h and stained with fluorescent antibodies against DAPI (blue), Aurora A (red) and α-tubulin (green). Placebo-treated cells in metaphase (white arrowhead) and anaphase (yellow arrowhead) are indicated. (D) The percentages of cells with Aurora A expression were assessed after treatment with placebo or roniciclib (100 nmol/L) for 24 h using immunofluorescence confocal microscopy. A minimum of 760 cells was counted for each condition. Roniciclib significantly decreased the proportion of cells with Aurora A expression in two MTC cell lines. Scale bar, 10 μm.